Pfizer To Use India Location To Concentrate On Indian Ailments
This article was originally published in PharmAsia News
When Pfizer stepped up its presence in the Indian pharmaceutical market, it did so to concentrate on drugs specific to Indian ailments. With the move to India, Pfizer plans to focus on cancer, diabetes, inflammation, neurological disorders and other ailments at the regional level. Among the plans are trials of Sutent (sunitinib malate) for combating kidney cancer. Pfizer's India presence also is aimed at diabetes, inflammation and neurological disorders as well as breast, cervical and lung cancers. (Click here for more
You may also be interested in...
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.